Analyst Ratings for Erasca Inc (ERAS)
ERAS Rating Summary
ERAS Price Target Summary
- Highest: $30.00 (Stifel)
- Lowest: $12.00 (Morgan Stanley)
- Average: $20.30
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$20.30 (+5.9%)
* Over Last 12-Mos
Rating Score: 7.7 / 10
Percentile Rank: 81%
Avg. $ Target:
$20.30 (+5.9%)
* Over Last 12-Mos
Rating Score: 7.7 / 10
Percentile Rank: 81%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/13/2026 | Goldman Sachs | Kevin Strang | New Coverage | Early-Stage Biotech (N/A) |
N/A (N/A) |
18.53 (19.17) |
3.45% | Details |
| 6/4/2026 | BofA Securities | Alec Stranahan | Upgrade | Neutral (Underperform) |
16.00 (9.00) |
13.18 (19.17) |
45.45% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
